<DOC>
	<DOCNO>NCT00006298</DOCNO>
	<brief_summary>The main goal study find immune system respond specific type HIV infection , know C HIV-1 , order develop vaccine type infection . The study involve Southern African population . The HIV-1 virus change rapidly many different subtypes find . In South Africa , limit data suggest Subtype C HIV-1 common . This study strive verify common subtype also look genetic difference immune response among newly infect individual . Results aid development vaccine specific certain geographical area .</brief_summary>
	<brief_title>Studies HIV-1 Infection Newly Infected Individuals Southern Africa</brief_title>
	<detailed_description>HIV-1 evolves rapidly multiple genetic subtypes isolate number geographic location . There limited data distribution subtypes Southern African HIVNET site . Data suggest subtype C HIV-1 predominates study design substantiate extend observation understand biological relationship HIV-1 subtypes , genetic variability , immune response . Earlier study conduct use individual seropositive 3 9 year advance disease status ; study test reactivity early stage infection . This assist rational selection prototypic isolate inclusion either single universal vaccine vaccine tailor specific subtypes/geographical region . Volunteers recruit Malawi , South Africa , Zambia , Zimbabwe . The early possible case seroconversion include . At enrollment , participant counsel appropriately HIV status demographic information obtain . Participants follow quarterly 12 month . Epidemiological , clinical , laboratory data collect physical exam blood draws visit . Blood sample use assess CD4 count , plasma viral load , genetic parameter , individual immune response . Participants seronegative whose status unknown test HIV visit , post-test counseling participant return clinic test result . In addition enrol HIV-infected uninfected volunteer , site contributes 5-ml blood sample 50 seronegative individual DNA extraction HLA genotyping .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Participants may eligible study : Are first HIVnegative later test HIVpositive ; HIVpositive evidence HIVnegative within 8 month prior first test HIVpositive ; HIVpositive one test HIVnegative another test . Exclusion Criteria Participants eligible study : Have mental disorder interferes agree study participate study . Are receive antiHIV treatment 4 week . Have tuberculosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>HIV Antibodies</keyword>
	<keyword>HIV-1</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>T-Lymphocytes , Cytotoxic</keyword>
	<keyword>Genotype</keyword>
	<keyword>Species Specificity</keyword>
	<keyword>Neutralization Tests</keyword>
	<keyword>Viral Load</keyword>
	<keyword>Alleles</keyword>
	<keyword>HLA Antigens</keyword>
	<keyword>Cross Reactions</keyword>
	<keyword>Immunodominant Epitopes</keyword>
	<keyword>Haplotypes</keyword>
</DOC>